Celcuity. Every tracked FinTwit mention of $CELC, newest first. 26 mentions since the first on Jul 23, 2025. See the price chart.
June 2026 · 2 mentions
Jun 3
Jacob Plieth — @BiotechObserver Looks like a typo. $CELC ph1b mPFS in mutant was 14.6mth, or 19.7mth with intermittent dosing. Viktoria-1 clearly underperformed that (for whatever reason).↗
Jun 1
Adam Feuerstein ✡️ — Happy ASCO Monday! Stocks be trading...
Pretty quiet day here, presentation wise, I think. ASCO really wants people to stay thru to the very end of the meeting, so they scheduled…↗
May 2026 · 2 mentions
May 18
Jacob Plieth — @jayg327 @financebully Take two, with apologies! $CELC https://t.co/2ahhdLkMQF↗
Jacob Plieth — Who won #ESMO25 and who lost? Via @ApexOnco
https://t.co/EWzHIIH1Ck
$IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $Z…↗
Oct 20
Jacob Plieth — Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz
Stocks to watch this morning: $GMAB $CELC $IOBT $MR…↗
Oct 18
Jacob Plieth — @NotGenentech @JackSha90859576 This is the official version $CELC https://t.co/03HA6ORQmS↗
Oct 18
Jacob Plieth — $CELC reveals OS data in wild-types, and sets the bar for gedatolisib's upcoming PIK3CAm catalyst https://t.co/8Kpk4Z10Pl #ESMO25
September 2025 · 1 mention
Sep 29
Jacob Plieth — $IOBT (-75% this am), $LPTX, $CELC & some other #ESMO25 late breakers, via @ApexOnco https://t.co/FAEqm9otw5 $EXEL $RHHBY $AZN↗
July 2025 · 12 mentions
Jul 28
Jacob Plieth — $CELC delivers with asset $PFE jettisoned for $5m. How do the data compare vs others? My analysis via @ApexOnco -> https://t.co/ZYdevZvCV8↗
Jul 28
Jacob Plieth — @avidresearch So lower than 96% (all grades) and 26% (gr3/4)? $CELC↗
Jul 28
Jacob Plieth — $CELC opens +210%. Market cap $1.6bn.↗
Jul 28
Jacob Plieth — So how did $PFE manage to get this so wrong? Limited gedatolisib monoRx activity? Decision to focus on other mechanisms like CDK2, CDK4, ER, KAT6? $CELC↗
Jacob Plieth — @JackSha90859576 I quite like the V-1 data, but there are some things that don't make sense. What's the actual MoA of gedatolisib? Why did $PFE sell it to $CELC for just $5m?↗
Oct 18
Jacob Plieth — R Hurvitz mentioning mPFS of 14.6mth for gedato triplet in PIK3CAm in phase 1 might have freaked people out, since Piqray+Faslodex (Victoria-1 comparator) has 11.0mth on its label.…↗
Oct 18
Jacob Plieth — Also we now have OS numbers from $CELC Victoria-1. Pretty high crossover, so let's wait to see what the FDA makes of this #ESMO25 https://t.co/RvrkRbaKHM↗
Oct 18
Jacob Plieth — Supplementing some $CELC gedatolisib data in Victoria-1 PIK3CA w/t, as presented this am at #ESMO25. Hyperglycaemia is indeed much lower (9.2% for doublet, 11.5% for triplet), but…↗
Oct 18
Adam Feuerstein ✡️ — Roche, Celcuity $CELC detail successful advanced breast cancer studies https://t.co/vRTOblO9Ki via @DrewQJoseph #ESMO25↗
Jul 28
Jacob Plieth — @alexsgrowth More relevant are other pan-PI3K/mTOR inhibitors, like $LLY samotolisib, and why these bombed. $CELC↗
Jul 28
Jacob Plieth — @avidresearch Yes, but that's quite a subjective statement. Actual numbers would have been more reassuring $CELC↗
Jul 28
Jacob Plieth — $CELC back-of-cigarette packet comps (PIK3CAm included just for completeness) https://t.co/4Sm52BTpYK↗
Jul 28
Jacob Plieth — Main bear point so far is $CELC saying virtually nothing about hyperglycaemia in Viktoria-1.↗
Jul 28
Jacob Plieth — $CELC PFS curves for the triplet & doublet PIK3CA-wt cohorts https://t.co/AeezMzJzrs↗